InVivo Therapeutics Holdings Corp. (NVIV) Closer to Commencing Human Study for Treatment of Spinal Cord Injuries
InVivo Therapeutics Holdings, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today detailed results of its meeting with the U.S. Food and Drug Administration (FDA) for discussion of the investigational device exemption (IDE) previously filed for InVivo’s biopolymer scaffolding for the treatment of acute spinal cord injuries. Before InVivo can advance to human clinical studies, the FDA must approve the company’s IDE filing, for which the FDA has agreed to an open dialogue as the application moves toward gaining approval. Following the meeting, the company said it anticipates that the biopolymer scaffolding device will be…